These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 26571844

  • 21. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K, Semba H, Fujii S, Tsumura S.
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [Abstract] [Full Text] [Related]

  • 26. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

  • 27. Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer.
    Lopes GL, Vattimo EF, Castro Junior Gd.
    J Bras Pneumol; 2015 Oct; 41(4):365-75. PubMed ID: 26398757
    [Abstract] [Full Text] [Related]

  • 28. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
    Skinner KE, Fernandes AW, Walker MS, Pavilack M, VanderWalde A.
    J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
    [Abstract] [Full Text] [Related]

  • 29. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M, Afatinib Compassionate Use Consortium (ACUC).
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [Abstract] [Full Text] [Related]

  • 30. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
    Graham J, Earnshaw S, Burslem K, Lim J.
    J Manag Care Spec Pharm; 2018 Jun; 24(6):544-553. PubMed ID: 29799327
    [Abstract] [Full Text] [Related]

  • 31. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, Pan H, Yang X, Xie S, Feng X, Lv Z, Wang Y, Chen Z, He J.
    World J Surg Oncol; 2017 Nov 06; 15(1):197. PubMed ID: 29110716
    [Abstract] [Full Text] [Related]

  • 32. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M.
    BMC Cancer; 2018 Jan 30; 18(1):106. PubMed ID: 29382302
    [Abstract] [Full Text] [Related]

  • 33. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
    Ke EE, Wu YL.
    Ther Adv Respir Dis; 2016 Jun 30; 10(3):256-64. PubMed ID: 26929305
    [Abstract] [Full Text] [Related]

  • 34. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations.
    Giuliani J, Remo A, Bonetti A.
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb 30; 17(1):5-8. PubMed ID: 27830967
    [Abstract] [Full Text] [Related]

  • 35. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
    Kuwako T, Imai H, Masuda T, Miura Y, Seki K, Yoshino R, Kaira K, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M.
    Cancer Chemother Pharmacol; 2015 Oct 30; 76(4):761-9. PubMed ID: 26254024
    [Abstract] [Full Text] [Related]

  • 36. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
    Reguart N, Remon J.
    Future Oncol; 2015 Oct 30; 11(8):1245-57. PubMed ID: 25629371
    [Abstract] [Full Text] [Related]

  • 37. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E, Grauslund M, Melchior LC, Costa JC, Sørensen JB, Urbanska EM.
    Lung Cancer; 2017 Nov 30; 113():14-17. PubMed ID: 29110841
    [Abstract] [Full Text] [Related]

  • 38. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
    Damyanov D, Koynov K, Naseva E, Bichev S.
    J BUON; 2015 Nov 30; 20(1):136-41. PubMed ID: 25778308
    [Abstract] [Full Text] [Related]

  • 39. Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
    Igawa S, Kasajima M, Ishihara M, Kimura M, Hiyoshi Y, Asakuma M, Otani S, Katono K, Sasaki J, Masuda N.
    Oncology; 2014 Nov 30; 87(4):215-23. PubMed ID: 25034225
    [Abstract] [Full Text] [Related]

  • 40. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W, Tufman A, Huber RM.
    Expert Rev Anticancer Ther; 2017 Feb 30; 17(2):143-155. PubMed ID: 27898252
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.